Nasdaq

Here's What To Expect From Johnson & Johnson's Q1

Johnson & Johnson stock (NYSE: JNJ) will report its Q1 2024 results on Tuesday, April 16. We expect the company to post revenue of $21.5 billion and earnings of $2.68, compared to the consensus ...
WebMD

Stelara for Crohn’s Disease and Ulcerative Colitis

Stelara is a biologic medicine used to treat moderate to severe Crohn’s disease and ulcerative colitis. Crohn’s disease and ulcerative colitis are inflammatory bowel diseases that cause inflammation ...
Forbes

Here’s What To Expect From Johnson & Johnson’s Q1

Johnson & Johnson stock (NYSE: JNJ) will report its Q1 2024 results on Tuesday, April 16. We expect the company to post revenue of $21.5 billion and earnings of $2.68, compared to the consensus ...